Meta-Analysis Data on Benzodiazepine Receptor Modulators for COPD Patients with Insomnia

A systematic review and meta-analysis following PRISMA guidelines evaluates the dual-temporal safety profile of benzodiazepine receptor positive allosteric modulators (PAMs) in COPD patients with comorbid insomnia. The study, authored by Xiao-Jiao Cui and registered with PROSPERO (CRD420251035164), assesses short-term sleep benefits against long-term pulmonary risks. Results indicate significant short-term improvements in sleep metrics but a potential increase in adverse respiratory outcomes with long-term use.

Use Cases

• Analyze the relationship between drug use and sleep metrics like total sleep time (TST) and sleep efficiency.
• Model the risk of adverse respiratory outcomes, including emergency visits and hospitalizations, based on long-term drug exposure.
• Compare short-term physiological parameters (FEV1, SaO2, PaO2) between treatment and placebo groups.
• Validate meta-analysis findings for clinical decision-making regarding short-term benefits versus long-term risks.

Strengths

• The analysis is structured around specific, clinically validated primary indicators for both short-term (TST, FEV1) and long-term (all-cause mortality, AECOPD events) assessment.
• The study follows the PRISMA guidelines for systematic reviews, suggesting a standardized methodological approach.
• Results include statistically significant p-values (e.g., p < 0.00001 for TST improvement) and odds ratios with confidence intervals (e.g., OR = 1.97 for emergency visits).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 3.0 MB PDF, which may require extraction to access underlying tabular data.

Provenance

Source

figshare

Collection Method

Systematic literature searches performed in target databases, followed by meta-analysis.

Freshness

Last updated 2026-04-29 05:52:43; freshness should be verified.